EC

Endocyte

- NASDAQ:ECYT
Last Updated 2024-04-09

LinkedIn Profile

Access Endocyte historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:ecyt 1120203 Apr 14th, 2024 12:00AM Endocyte 3.4K 17.00 Open Apr 13th, 2024 10:57PM Apr 14th, 2024 10:56AM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, and Companion Imaging Open Purdue Research Park West Lafayette IN US 47906 Endocyte Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Apr 13th, 2024 12:00AM Endocyte 3.4K 17.00 Open Apr 12th, 2024 10:48PM Apr 13th, 2024 11:23AM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, and Companion Imaging Open Purdue Research Park West Lafayette IN US 47906 Endocyte Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Apr 12th, 2024 12:00AM Endocyte 3.4K 17.00 Open Apr 11th, 2024 10:53PM Apr 12th, 2024 08:18AM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, and Companion Imaging Open Purdue Research Park West Lafayette IN US 47906 Endocyte Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Apr 11th, 2024 12:00AM Endocyte 3.4K 17.00 Open Apr 10th, 2024 11:26PM Apr 11th, 2024 11:03AM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, and Companion Imaging Open Purdue Research Park West Lafayette IN US 47906 Endocyte Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Apr 10th, 2024 12:00AM Endocyte 3.4K 17.00 Open Apr 9th, 2024 10:56PM Apr 10th, 2024 05:11PM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, and Companion Imaging Open Purdue Research Park West Lafayette IN US 47906 Endocyte Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Apr 9th, 2024 12:00AM Endocyte 3.4K 17.00 Open Apr 8th, 2024 11:07PM Apr 9th, 2024 09:53AM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, and Companion Imaging Open Purdue Research Park West Lafayette IN US 47906 Endocyte Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Apr 8th, 2024 12:00AM Endocyte 3.4K 17.00 Open Apr 7th, 2024 11:32PM Apr 8th, 2024 06:50PM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, and Companion Imaging Open Purdue Research Park West Lafayette IN US 47906 Endocyte Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Apr 7th, 2024 12:00AM Endocyte 3.4K 17.00 Open Apr 6th, 2024 11:03PM Apr 6th, 2024 11:03PM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, and Companion Imaging Open Purdue Research Park West Lafayette IN US 47906 Endocyte Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Apr 6th, 2024 12:00AM Endocyte 3.4K 17.00 Open Apr 5th, 2024 11:03PM Apr 5th, 2024 11:03PM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, and Companion Imaging Open Purdue Research Park West Lafayette IN US 47906 Endocyte Health Care Pharmaceuticals & Biotechnology
nasdaq:ecyt 1120203 Apr 5th, 2024 12:00AM Endocyte 3.4K 17.00 Open Apr 4th, 2024 11:30PM Apr 4th, 2024 11:30PM Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, entering phase 3 for metastatic castration resistant prostate cancer (mCRPC). Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic, where it will be studied in osteosarcoma. Open Cancer, mCRPC, CAR-T, Targeted drug therapy, and Companion Imaging Open Purdue Research Park West Lafayette IN US 47906 Endocyte Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.